Skip to main content
TipRanks
Go Ultimate75% OFF

Haemonetics (HAZ) Stock Statistics & Valuation Metrics

1 Followers

Total Valuation

Haemonetics has a market cap or net worth of EUR 5.00B. The enterprise value is EUR 5.76B.

Market Cap
EUR 5.00B
Enterprise Value
EUR 5.76B

Share Statistics

Haemonetics has 45,537,510 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
45,537,510
Owned by Insiders
1.82%
Owned by Institutions
94.81%

Financial Efficiency

Haemonetics’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 8.66%.

Return on Equity (ROE)
0.12
Return on Assets (ROA)
0.04
Return on Invested Capital (ROIC)
8.66%
Return on Capital Employed (ROCE)
0.11
Revenue Per Employee
443.35K
Profits Per Employee
32.34K
Employee Count
3,009
Asset Turnover
0.56
Inventory Turnover
1.93

Valuation Ratios

The current PE Ratio of Haemonetics is 52.93. Haemonetics’s PEG ratio is -1.56.

PE Ratio
52.93
PS Ratio
3.96
PB Ratio
6.08
Price to FCF
18.01
Price to Operating Cash Flow
15.85
PEG Ratio
-1.56

Income Statement

In the last 12 months, Haemonetics had revenue of 1.33B and earned 97.31M in profits. Earnings per share was 2.05.

Revenue
1.33B
Gross Profit
743.59M
Operating Income
241.40M
Pretax Income
128.03M
Net Income
97.31M
EBITDA
268.45M
Earnings Per Share (EPS)
2.05

Cash Flow

In the last 12 months, operating cash flow was 344.93M and capital expenditures -41.12M, giving a free cash flow of 303.81M billion.

Operating Cash Flow
344.93M
Free Cash Flow
303.81M
Free Cash Flow per Share
6.68

Dividends & Yields

Haemonetics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
5.55%
Earnings Yield
1.90%

Stock Price Statistics

Beta
-0.06
52-Week Price Change
70.54%
50-Day Moving Average
100.17
200-Day Moving Average
70.45
Relative Strength Index (RSI)
60.69
Average Volume (3m)
12

Important Dates

Haemonetics upcoming earnings date is Feb 11, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 05, 2026
Next Earnings Date
Feb 11, 2027
Ex-Dividend Date
―

Financial Position

Haemonetics as a current ratio of 2.95, with Debt / Equity ratio of 153.78%

Current Ratio
2.95
Quick Ratio
1.87
Debt to Market Cap
0.48
Net Debt to EBITDA
3.65
Interest Coverage Ratio
8.41

Taxes

In the past 12 months, Haemonetics has paid 30.72M in taxes.

Income Tax
30.72M
Effective Tax Rate
0.24

Enterprise Valuation

Haemonetics EV to EBITDA ratio is 22.85, with an EV/FCF ratio of 20.86.

EV to Sales
4.58
EV to EBITDA
22.85
EV to Free Cash Flow
20.86
EV to Operating Cash Flow
18.38

Balance Sheet

Haemonetics has EUR 260.71M in cash and marketable securities with EUR 1.12B in debt, giving a net cash position of -EUR 863.05M billion.

Cash & Marketable Securities
EUR 260.71M
Total Debt
EUR 1.12B
Net Cash
-EUR 863.05M
Net Cash Per Share
-EUR 18.95
Tangible Book Value Per Share
-EUR 4.07

Margins

Gross margin is 58.83%, with operating margin of 18.34%, and net profit margin of 7.52%.

Gross Margin
58.83%
Operating Margin
18.34%
Pretax Margin
10.27%
Net Profit Margin
7.52%
EBITDA Margin
20.06%
EBIT Margin
12.14%

Analyst Forecast

The average price target for Haemonetics is EUR 132.06, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
EUR 132.06
Price Target Upside
20.05% Upside
Analyst Consensus
Strong Buy
Analyst Count
11
Revenue Growth Forecast
-1.20%
EPS Growth Forecast
-37.57%

Scores

Smart Score
10
AI Score
―